JP2016028035A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016028035A5 JP2016028035A5 JP2015159434A JP2015159434A JP2016028035A5 JP 2016028035 A5 JP2016028035 A5 JP 2016028035A5 JP 2015159434 A JP2015159434 A JP 2015159434A JP 2015159434 A JP2015159434 A JP 2015159434A JP 2016028035 A5 JP2016028035 A5 JP 2016028035A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- cells
- deletion
- virus
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cell Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 244000309459 oncolytic virus Species 0.000 description 4
- 101100012019 Mus musculus Etv4 gene Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010001258 Adenoviral infections Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15682209P | 2009-03-02 | 2009-03-02 | |
| US61/156,822 | 2009-03-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553041A Division JP6072414B2 (ja) | 2009-03-02 | 2010-03-02 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018035231A Division JP6817979B2 (ja) | 2009-03-02 | 2018-02-28 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016028035A JP2016028035A (ja) | 2016-02-25 |
| JP2016028035A5 true JP2016028035A5 (enExample) | 2017-02-16 |
| JP6375273B2 JP6375273B2 (ja) | 2018-08-15 |
Family
ID=42710189
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553041A Active JP6072414B2 (ja) | 2009-03-02 | 2010-03-02 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2015159434A Active JP6375273B2 (ja) | 2009-03-02 | 2015-08-12 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2018035231A Active JP6817979B2 (ja) | 2009-03-02 | 2018-02-28 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2020019294A Pending JP2020078326A (ja) | 2009-03-02 | 2020-02-07 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2021158698A Active JP7326396B2 (ja) | 2009-03-02 | 2021-09-29 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553041A Active JP6072414B2 (ja) | 2009-03-02 | 2010-03-02 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018035231A Active JP6817979B2 (ja) | 2009-03-02 | 2018-02-28 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2020019294A Pending JP2020078326A (ja) | 2009-03-02 | 2020-02-07 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2021158698A Active JP7326396B2 (ja) | 2009-03-02 | 2021-09-29 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9073980B2 (enExample) |
| EP (4) | EP2403951B1 (enExample) |
| JP (5) | JP6072414B2 (enExample) |
| KR (4) | KR101922539B1 (enExample) |
| CY (1) | CY1122385T1 (enExample) |
| DK (2) | DK3029144T3 (enExample) |
| ES (2) | ES2557812T3 (enExample) |
| HR (2) | HRP20151396T1 (enExample) |
| HU (2) | HUE026386T2 (enExample) |
| LT (1) | LT3029144T (enExample) |
| PL (2) | PL3029144T3 (enExample) |
| PT (2) | PT2403951E (enExample) |
| SI (2) | SI2403951T1 (enExample) |
| SM (2) | SMT201900565T1 (enExample) |
| WO (1) | WO2010101921A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2403951E (pt) | 2009-03-02 | 2016-01-29 | Univ California | Mutantes de adenovírus e1a e e1b de tumores |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| CN111705116A (zh) | 2013-07-19 | 2020-09-25 | 路德维格癌症研究有限公司 | 全基因组且靶向的单体型重构 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| EP3519442A4 (en) * | 2016-09-27 | 2020-06-17 | EpicentRx, Inc. | Immunomodulatory fusion proteins |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
| US20190352669A1 (en) * | 2017-01-30 | 2019-11-21 | Epicentrx, Inc. | Tumor selective tata-box and caat-box mutants |
| SG11201906973TA (en) * | 2017-01-30 | 2019-08-27 | Epicentrx Inc | Multiple transgene recombinant adenovirus |
| EP3610003A4 (en) * | 2017-04-10 | 2021-01-06 | EpicentRx, Inc. | RECOMBINANT VIRUS PRODUCTION PROCESS |
| EA201990822A1 (ru) * | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| EP3630959A4 (en) * | 2017-05-24 | 2021-03-17 | EpicentRx, Inc. | ANTI-ANGIOGENIC ADENOVIRUS |
| CN120796389A (zh) | 2017-05-26 | 2025-10-17 | 埃皮森特Rx股份有限公司 | 携带转基因的重组腺病毒 |
| IL273626B2 (en) | 2017-09-27 | 2025-07-01 | Epicentrx Inc | Immunomodulatory fusion proteins |
| US11510901B2 (en) | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| EP3773649A4 (en) | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| WO2020046130A1 (en) * | 2018-08-31 | 2020-03-05 | Orca Therapeutics B.V. | Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells |
| US20220403438A1 (en) | 2019-10-08 | 2022-12-22 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
| CN114262691A (zh) * | 2020-09-16 | 2022-04-01 | 杭州康万达医药科技有限公司 | 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途 |
| EP4554559A1 (en) | 2022-07-13 | 2025-05-21 | EpicentRx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
| CN118931897A (zh) * | 2024-06-27 | 2024-11-12 | 中山大学 | 一种识别肿瘤细胞并诱导其焦亡的基因、重组载体和重组病毒及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643567A (en) | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US5352775A (en) | 1991-01-16 | 1994-10-04 | The Johns Hopkins Univ. | APC gene and nucleic acid probes derived therefrom |
| JPH06509578A (ja) | 1991-07-26 | 1994-10-27 | ユニバーシティ・オブ・ロチェスター | 悪性細胞利用による癌治療法 |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| US5902925A (en) | 1996-07-01 | 1999-05-11 | Integrated Sensor Solutions | System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature |
| GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
| US20050287120A1 (en) | 1997-03-21 | 2005-12-29 | Fisher Paul B | Cancer - targeted viral vectors |
| AU772544B2 (en) * | 1999-01-28 | 2004-04-29 | Onyx Pharmaceuticals | E1B-deleted adenoviral shuttle vectors |
| US6764674B1 (en) * | 1999-01-28 | 2004-07-20 | Onyx Pharmaceuticals Inc. | Adenovirus E1B shuttle vectors |
| WO2001083797A2 (en) * | 2000-04-28 | 2001-11-08 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
| WO2002018550A1 (en) * | 2000-08-25 | 2002-03-07 | The General Hospital Corporation | Selective precipitation of viruses |
| CN1183250C (zh) * | 2000-12-01 | 2005-01-05 | 卫健生物科技有限公司 | 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法 |
| GB0117198D0 (en) | 2001-07-13 | 2001-09-05 | Btg Int Ltd | Anti-neoplastic viral agents |
| WO2004009768A2 (en) | 2002-07-18 | 2004-01-29 | Invitrogen Corporation | Viral vectors containing recombination sites |
| WO2004020971A2 (en) * | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| US20060270016A1 (en) * | 2003-11-14 | 2006-11-30 | Holm Per S | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
| EP1830864A2 (de) * | 2004-12-31 | 2007-09-12 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| KR101252065B1 (ko) * | 2007-04-20 | 2013-04-12 | 다카라 바이오 가부시키가이샤 | 유전자 치료를 위한 벡터 |
| PT2403951E (pt) | 2009-03-02 | 2016-01-29 | Univ California | Mutantes de adenovírus e1a e e1b de tumores |
-
2010
- 2010-03-02 PT PT107492050T patent/PT2403951E/pt unknown
- 2010-03-02 PL PL15182086T patent/PL3029144T3/pl unknown
- 2010-03-02 KR KR1020177017391A patent/KR101922539B1/ko active Active
- 2010-03-02 SM SM20190565T patent/SMT201900565T1/it unknown
- 2010-03-02 EP EP10749205.0A patent/EP2403951B1/en active Active
- 2010-03-02 PL PL10749205T patent/PL2403951T3/pl unknown
- 2010-03-02 EP EP19171420.3A patent/EP3591059B1/en active Active
- 2010-03-02 SI SI201031077T patent/SI2403951T1/sl unknown
- 2010-03-02 ES ES10749205.0T patent/ES2557812T3/es active Active
- 2010-03-02 LT LT15182086T patent/LT3029144T/lt unknown
- 2010-03-02 SI SI201031944T patent/SI3029144T1/sl unknown
- 2010-03-02 US US13/254,825 patent/US9073980B2/en active Active
- 2010-03-02 DK DK15182086.7T patent/DK3029144T3/da active
- 2010-03-02 JP JP2011553041A patent/JP6072414B2/ja active Active
- 2010-03-02 EP EP15182086.7A patent/EP3029144B1/en active Active
- 2010-03-02 DK DK10749205.0T patent/DK2403951T3/en active
- 2010-03-02 HU HUE10749205A patent/HUE026386T2/en unknown
- 2010-03-02 ES ES15182086T patent/ES2750305T3/es active Active
- 2010-03-02 KR KR1020117022884A patent/KR101752910B1/ko active Active
- 2010-03-02 KR KR1020197025813A patent/KR102150027B1/ko active Active
- 2010-03-02 HU HUE15182086A patent/HUE046565T2/hu unknown
- 2010-03-02 KR KR1020187012031A patent/KR102020018B1/ko active Active
- 2010-03-02 EP EP22178897.9A patent/EP4123030A1/en active Pending
- 2010-03-02 WO PCT/US2010/025926 patent/WO2010101921A2/en not_active Ceased
- 2010-03-02 PT PT151820867T patent/PT3029144T/pt unknown
- 2010-03-02 HR HRP20151396T patent/HRP20151396T1/hr unknown
-
2015
- 2015-05-26 US US14/722,021 patent/US20160017294A1/en not_active Abandoned
- 2015-08-12 JP JP2015159434A patent/JP6375273B2/ja active Active
- 2015-12-31 SM SM201500329T patent/SMT201500329B/it unknown
-
2018
- 2018-02-28 JP JP2018035231A patent/JP6817979B2/ja active Active
- 2018-08-08 US US16/058,886 patent/US10876097B2/en active Active
-
2019
- 2019-10-03 HR HRP20191808TT patent/HRP20191808T1/hr unknown
- 2019-10-10 CY CY20191101067T patent/CY1122385T1/el unknown
-
2020
- 2020-02-07 JP JP2020019294A patent/JP2020078326A/ja active Pending
- 2020-11-20 US US17/100,671 patent/US11618888B2/en active Active
-
2021
- 2021-09-29 JP JP2021158698A patent/JP7326396B2/ja active Active
-
2022
- 2022-11-23 US US17/993,182 patent/US12195766B2/en active Active
-
2024
- 2024-12-05 US US18/969,407 patent/US20250327037A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016028035A5 (enExample) | ||
| Davola et al. | Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? | |
| Wong et al. | Oncolytic viruses for cancer therapy: overcoming the obstacles | |
| Doronin et al. | Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy | |
| Seymour et al. | Oncolytic viruses: finally delivering | |
| Cheng et al. | Oncolytic replication of E1b-deleted adenoviruses | |
| Ko et al. | Development of transcriptionally regulated oncolytic adenoviruses | |
| SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
| EP4043021A3 (en) | Oncolytic tumor viruses and methods of use | |
| Kim et al. | Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy | |
| JP2019523008A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| EA201690545A1 (ru) | Онколитические аденовирусы, несущие гетерологичные гены | |
| HUE026386T2 (en) | Tumor-selective adenovirus e1a and e1b mutants | |
| JP2019528793A5 (enExample) | ||
| Kurisetty et al. | Preclinical safety and activity of recombinant VSV‐IFN‐β in an immunocompetent model of squamous cell carcinoma of the head and neck | |
| Yokoda et al. | Oncolytic virotherapy in upper gastrointestinal tract cancers | |
| Zhang et al. | shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy | |
| JP4361954B2 (ja) | アデノウィルス核酸を含有する医薬用組成物 | |
| JP2018518986A5 (enExample) | ||
| Xu et al. | HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy | |
| JP2016530890A5 (enExample) | ||
| Gao et al. | A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs | |
| Wei et al. | Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells | |
| Thomas et al. | Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors |